Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity
Open Access
- 30 April 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (13) , 1593-1603
- https://doi.org/10.1093/hmg/ddm109
Abstract
Spinal and bulbar muscular atrophy (SBMA) is a progressive neurodegenerative disease caused by an expansion of the polyglutamine tract in the androgen receptor (AR). Here, we investigated the regulation of AR phosphorylation in order to understand factors that may modify SBMA disease progression. We show that expanded polyglutamine AR is phosphorylated by Akt. Substitution of the AR at two Akt consensus sites, S215 and S792, with aspartate, which mimics phosphorylation, reduces ligand binding, ligand-dependent nuclear translocation, transcriptional activation and toxicity of expanded polyglutamine AR. Co-expression of constitutively active Akt and the AR has similar consequences, which are blocked by alanine substitutions at residues 215 and 792. Furthermore, in motor neuron-derived MN-1 cells toxicity associated with polyglutamine-expanded AR is rescued by co-expression with Akt. Insulin-like growth factor-1 (IGF-1) stimulation, which activates several cell survival promoting pathways, also reduces toxicity of the expanded polyglutamine AR in MN-1 cells, in a manner dependent upon phospho-inositol-3-kinase. IGF-1 rescue of AR toxicity is diminished by alanine substitutions at the Akt consensus sites. These results highlight potential targets for therapeutic intervention in SBMA.Keywords
This publication has 35 references indexed in Scilit:
- Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in modelJournal of Clinical Investigation, 2006
- Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzleGenes & Development, 2006
- Pathogenesis, animal models and therapeutics in Spinal and bulbar muscular atrophy (SBMA)Experimental Neurology, 2006
- Targeting protein aggregation in neurodegeneration – lessons from polyglutamine disordersEmerging Therapeutic Targets, 2006
- Castration Restores Function and Neurofilament Alterations of Aged Symptomatic Males in a Transgenic Mouse Model of Spinal and Bulbar Muscular AtrophyJournal of Neuroscience, 2004
- The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neuronsFrontiers in Neuroendocrinology, 2004
- Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophyNature Medicine, 2003
- Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous womenNeurology, 2002
- Testosterone Reduction Prevents Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular AtrophyNeuron, 2002
- Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophyNature, 1991